| Company Name: |
Elucigen bio |
| Tel: |
13501719342 13501719342 |
| Email: |
wayne.zheng@elucigenbio.com |
|
| | N-[(3S)-3-(2-Chloro-5-fluorophenyl)-6-(5-cyano[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide Basic information |
| Product Name: | N-[(3S)-3-(2-Chloro-5-fluorophenyl)-6-(5-cyano[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide | | Synonyms: | N-[(3S)-3-(2-Chloro-5-fluorophenyl)-6-(5-cyano[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide;(S)-RLY-2608;(S)-N-(3-(2-Chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide;N-[(3S)-3-(2-chloro-5-fluoro-phenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxo-isoindolin-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide;(S)-Zovegalisib | | CAS: | 2733573-93-6 | | MF: | C29H14ClF5N6O2 | | MW: | 608.91 | | EINECS: | | | Product Categories: | | | Mol File: | 2733573-93-6.mol | ![N-[(3S)-3-(2-Chloro-5-fluorophenyl)-6-(5-cyano[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide Structure](CAS/20210305/GIF/2733573-93-6.gif) |
| | N-[(3S)-3-(2-Chloro-5-fluorophenyl)-6-(5-cyano[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide Chemical Properties |
| density | 1.61±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | | pka | 11.06±0.40(Predicted) | | form | Solid | | color | White to off-white |
| | N-[(3S)-3-(2-Chloro-5-fluorophenyl)-6-(5-cyano[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide Usage And Synthesis |
| Uses | (S)-RLY-2608 is an S-enantiomer of of RLY-2608 (HY-153306). RLY-2608 is an orally active first-in-class allosteric mutant-selective inhibitor of PI3Ka with anti-tumor activity[1]. | | References | [1] Andreas Varkaris, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer Discov. 2023 Nov 2. DOI:10.1158/2159-8290.CD-23-0944 |
| | N-[(3S)-3-(2-Chloro-5-fluorophenyl)-6-(5-cyano[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide Preparation Products And Raw materials |
|